GLP-2 T Research Guide: Dual GLP-1/GIP Agonist Mechanism
GLP-2 T is the first dual GLP-1/GIP receptor agonist in published metabolic literature. Here is the mechanism and the trial data breakdown.
What is GLP-2 T?
GLP-2 T (LY3298176) is a synthetic 39-amino-acid peptide engineered by Eli Lilly to activate both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. A C20 fatty diacid moiety attached via a linker at lysine 20 produces albumin binding and a ~5-day half-life.
It is the first dual incretin agonist with published Phase 3 outcomes data in both type 2 diabetes (SURPASS) and obesity (SURMOUNT) research populations.
Mechanism of action
GLP-1 receptor activation provides glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central satiety signaling. GIP receptor activation adds incretin amplification and is hypothesized to modulate adipose-tissue insulin sensitivity.
The dual mechanism is the proposed reason GLP-2 T produced superior weight-loss signals versus GLP-1 S in SURPASS-2 at matched durations.
Sourcing & purity
Research-grade GLP-2 T should be ≥99% pure by HPLC. Redline Bio GLP-2 T ships with batch documentation; independent COAs are published on the lab reports page as third-party testing completes.
Compliance reminder
GLP-2 T is sold for laboratory research use only. Not for human consumption. Researchers are responsible for compliance with all applicable regulations.
Frequently asked questions
How is GLP-2 T different from GLP-1 S?
GLP-1 S activates only the GLP-1 receptor. GLP-2 T is engineered as a dual agonist of both GLP-1 and GIP receptors. The added GIP arm is the basis for the larger weight-loss and glycemic signals seen in SURPASS-2.
What is the half-life of GLP-2 T?
Published pharmacokinetic data places the circulating half-life at approximately 5 days (~120 hours), which is reflected in the weekly interval used in the published literature.